Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells

S. Sridhar, A. A. Ali, Y. Liang, M. F. El Etreby, R. W. Lewis, M. V. Kumar

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Androgen ablation therapy induces apoptosis only in androgen-sensitive prostate cancer cells; therefore, other cytotoxic drugs are being used to induce apoptosis in androgen-refractory cells. Mifepristone, an antiprogestin used individually or together with the antiestrogen Tamoxifen, has been recommended for induction of cell death and treatment of several hormonal cancers. However, little is known about the mechanism of action of these drugs in prostate cancer. Therefore, we investigated the effect of Mifepristone on the tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) pathway, a newly identified and very effective member of tumor necrosis factor-α family. Mifepristone and Tamoxifen induced significant expression of death receptors in prostate cancer cells in vitro and in xenografts. However, Mifepristone in combination with Tamoxifen did not increase prostate cancer cell death compared with their individual values. The involvement of the TRAIL pathway was further confirmed by the activation of caspase-8 in Mifepristone-treated cells. This was followed by truncation of Bid, confirming that Mifepristone activates the TRAIL pathway. This knowledge is being used to design a combination treatment of TRAIL and Mifepristone to induce significant apoptosis in prostate cancer cells.

Original languageEnglish (US)
Pages (from-to)7179-7183
Number of pages5
JournalCancer Research
Volume61
Issue number19
StatePublished - Oct 1 2001

Fingerprint

Mifepristone
Prostatic Neoplasms
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Tamoxifen
Androgens
Cell Death
Death Domain Receptors
Estrogen Receptor Modulators
Caspase 8
Heterografts
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sridhar, S., Ali, A. A., Liang, Y., El Etreby, M. F., Lewis, R. W., & Kumar, M. V. (2001). Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Research, 61(19), 7179-7183.

Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells. / Sridhar, S.; Ali, A. A.; Liang, Y.; El Etreby, M. F.; Lewis, R. W.; Kumar, M. V.

In: Cancer Research, Vol. 61, No. 19, 01.10.2001, p. 7179-7183.

Research output: Contribution to journalArticle

Sridhar, S, Ali, AA, Liang, Y, El Etreby, MF, Lewis, RW & Kumar, MV 2001, 'Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells', Cancer Research, vol. 61, no. 19, pp. 7179-7183.
Sridhar, S. ; Ali, A. A. ; Liang, Y. ; El Etreby, M. F. ; Lewis, R. W. ; Kumar, M. V. / Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells. In: Cancer Research. 2001 ; Vol. 61, No. 19. pp. 7179-7183.
@article{3632dc1f18e84be6b179862e933bcc5b,
title = "Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells",
abstract = "Androgen ablation therapy induces apoptosis only in androgen-sensitive prostate cancer cells; therefore, other cytotoxic drugs are being used to induce apoptosis in androgen-refractory cells. Mifepristone, an antiprogestin used individually or together with the antiestrogen Tamoxifen, has been recommended for induction of cell death and treatment of several hormonal cancers. However, little is known about the mechanism of action of these drugs in prostate cancer. Therefore, we investigated the effect of Mifepristone on the tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) pathway, a newly identified and very effective member of tumor necrosis factor-α family. Mifepristone and Tamoxifen induced significant expression of death receptors in prostate cancer cells in vitro and in xenografts. However, Mifepristone in combination with Tamoxifen did not increase prostate cancer cell death compared with their individual values. The involvement of the TRAIL pathway was further confirmed by the activation of caspase-8 in Mifepristone-treated cells. This was followed by truncation of Bid, confirming that Mifepristone activates the TRAIL pathway. This knowledge is being used to design a combination treatment of TRAIL and Mifepristone to induce significant apoptosis in prostate cancer cells.",
author = "S. Sridhar and Ali, {A. A.} and Y. Liang and {El Etreby}, {M. F.} and Lewis, {R. W.} and Kumar, {M. V.}",
year = "2001",
month = "10",
day = "1",
language = "English (US)",
volume = "61",
pages = "7179--7183",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells

AU - Sridhar, S.

AU - Ali, A. A.

AU - Liang, Y.

AU - El Etreby, M. F.

AU - Lewis, R. W.

AU - Kumar, M. V.

PY - 2001/10/1

Y1 - 2001/10/1

N2 - Androgen ablation therapy induces apoptosis only in androgen-sensitive prostate cancer cells; therefore, other cytotoxic drugs are being used to induce apoptosis in androgen-refractory cells. Mifepristone, an antiprogestin used individually or together with the antiestrogen Tamoxifen, has been recommended for induction of cell death and treatment of several hormonal cancers. However, little is known about the mechanism of action of these drugs in prostate cancer. Therefore, we investigated the effect of Mifepristone on the tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) pathway, a newly identified and very effective member of tumor necrosis factor-α family. Mifepristone and Tamoxifen induced significant expression of death receptors in prostate cancer cells in vitro and in xenografts. However, Mifepristone in combination with Tamoxifen did not increase prostate cancer cell death compared with their individual values. The involvement of the TRAIL pathway was further confirmed by the activation of caspase-8 in Mifepristone-treated cells. This was followed by truncation of Bid, confirming that Mifepristone activates the TRAIL pathway. This knowledge is being used to design a combination treatment of TRAIL and Mifepristone to induce significant apoptosis in prostate cancer cells.

AB - Androgen ablation therapy induces apoptosis only in androgen-sensitive prostate cancer cells; therefore, other cytotoxic drugs are being used to induce apoptosis in androgen-refractory cells. Mifepristone, an antiprogestin used individually or together with the antiestrogen Tamoxifen, has been recommended for induction of cell death and treatment of several hormonal cancers. However, little is known about the mechanism of action of these drugs in prostate cancer. Therefore, we investigated the effect of Mifepristone on the tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) pathway, a newly identified and very effective member of tumor necrosis factor-α family. Mifepristone and Tamoxifen induced significant expression of death receptors in prostate cancer cells in vitro and in xenografts. However, Mifepristone in combination with Tamoxifen did not increase prostate cancer cell death compared with their individual values. The involvement of the TRAIL pathway was further confirmed by the activation of caspase-8 in Mifepristone-treated cells. This was followed by truncation of Bid, confirming that Mifepristone activates the TRAIL pathway. This knowledge is being used to design a combination treatment of TRAIL and Mifepristone to induce significant apoptosis in prostate cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=0035476850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035476850&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 7179

EP - 7183

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 19

ER -